Home World News FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met... World News FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 866 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 As Use of Genomic Data Expands in Cancer Care, Patients Share... December 3, 2019 Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer August 2, 2019 Cómo solicitar Medicare cuando tiene cáncer December 12, 2023 Load more HOT NEWS FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular... Courageous children receive Star Awards in virtual celebration First targeted treatment approved for advanced prostate cancer on NHS in...